Drug Profile

NTX 1955

Alternative Names: NTX-1955; RO-7308480

Latest Information Update: 28 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Roche
Developer Newleos Therapeutics; Roche
Class Anxiolytics; Behavioural disorder therapies
Mechanism of Action GABA A receptor positive allosteric modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Generalised anxiety disorder

Most Recent Events

28 Dec 2025 No recent reports of development identified for phase-I development in Generalised-anxiety-disorder(In volunteers) in United Kingdom (PO, Capsule)
08 Aug 2025 Newleos Therapeutics initiates the phase I CO2 challenge trial (In volunteers) in the Netherlands (CTIS2025-522281-68-00)
30 Jul 2025 Phase-I clinical trials in Generalised anxiety disorders in European Union (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com